has recommended GlaxoSmithKline’s (GSK) ZEJULA (niraparib) for some forms of ovarian, fallopian tube, and peritoneal cancer. Following a period of restricted access, the once-a-day capsule will ...

GSK acquired Zejula as part of its $5.1 billion takeover of Tesaro in 2018, along with other oncology drug candidates, including latecomer PD-1 inhibitor Jemperli (dostarlimab) and others ...

GSK (NYSE:GSK) reported mixed results from a Phase 3 study evaluating Zejula, or niraparib, and Jemperli, or dostarlimab, in the treatment of advanced ovarian cancer. The U.K. drugmaker said that ...

along with providing access to new scientific capabilities,” says GSK CEO Emma Walmsley in the release. TESARO’s drug Zejula is a PARP inhibitor approved for treating ovarian cancer. PARP inhibitors ...

GSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks ...

To offer further encouragement, Dame Emma Walmsley, the company’s chief, offered a more optimistic outlook than expected for ...

One of the most important launches for Novartis in recent years is off with a bang. | One of the most important launches for ...

GSK plc GSK reported fourth-quarter 2024 core ... it received approval in the EU in January 2024. Zejula sales fell 3% in the quarter. Though the drug’s U.S. sales were adversely impacted ...